# Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

> **NCT00903409** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 188 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Simvastatin + Lovaza® (omega-3-acid ethyl esters)

## Key facts

- **NCT ID:** NCT00903409
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-15
- **Primary completion:** 2008-06-27
- **Final completion:** 2008-06-27
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903409, "Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00903409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*